A Single-Arm Open-Label Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
Latest Information Update: 19 Feb 2025
Price :
$35 *
At a glance
- Drugs CSB-001 (Primary)
- Indications Corneal disorders
- Focus Adverse reactions
- Sponsors Claris Biotherapeutics
- 11 Feb 2025 Planned End Date changed from 28 Feb 2025 to 31 Aug 2025.
- 11 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 May 2025.
- 03 Oct 2024 The protocol has been amended to change in Interventional Study Model as parallel assignment, decrease in number of drug arms and allocation is changed to Non-Randomized.